Posted by Michael Wonder on 20 Aug 2024
GSK receives US FDA breakthrough therapy designation for its B7-H3 targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer
20 August 2024 - Regulatory designation based on promising early clinical evidence observed with GSK5764227 in this tumour type.
GSK announced today that the US FDA has granted breakthrough therapy designation for GSK5764227, the Company’s investigational B7-H3-targeted antibody drug conjugate being evaluated for the treatment of patients with extensive-stage small-cell lung cancer with disease progression on or after platinum-based chemotherapy.
